Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03MTN
|
||||
| Former ID |
DCL000561
|
||||
| Drug Name |
Mepolizumab
|
||||
| Synonyms |
Bosatria; Scoparianoside C; SB 240563; Immunoglobulin G1, anti-(human interleukin 5) (human-mouse monoclonal SB-240563 gamma1-chain), disulfide with human-mouse monoclonal SB-240563 kappa-chain, dimer; (2S,3S,4S,5R,6R)-6-[[(3S,4aR,6aR,6bS,8aS,14aR,14bR)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,13,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxane-2-carboxylic acid
|
||||
| Drug Type |
Monoclonal antibody
|
||||
| Indication | Severe asthma; Nasal polyposis [ICD9: 471, 493; ICD10:J33, J45] | Approved | [536958], [542665] | ||
| Asthma; Eosinophilic oesophagitis; Hypereosinophilia [ICD10:D72.1, J40-J44, J47, J45, L20] | Phase 2/3 | [889326], [889327], [889338], [889339], [889353], [889366], [889367], [889370], [889372], [889380], [889381], [889382], [889385], [889393], [889394], [889409], [889417], [889423], [889430], [889432], [889435], [889436] | |||
| Company |
MedImmune
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C42H66O12
|
||||
| PubChem Compound ID | |||||
| SuperDrug ATC ID |
L04AC06
|
||||
| Target and Pathway | |||||
| Target(s) | Interleukin-5 | Target Info | Modulator | ||
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| Jak-STAT signaling pathway | |||||
| Hematopoietic cell lineage | |||||
| T cell receptor signaling pathway | |||||
| Fc epsilon RI signaling pathway | |||||
| Intestinal immune network for IgA production | |||||
| Asthma | |||||
| Autoimmune thyroid disease | |||||
| Inflammatory bowel disease (IBD) | |||||
| Allograft rejection | |||||
| PANTHER Pathway | Interleukin signaling pathway | ||||
| PathWhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | ||||
| References | |||||
| Ref 536958 | Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53. | ||||
| Ref 542665 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7685). | ||||
| Ref 889326 | ClinicalTrials.gov (NCT00086658) Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) | ||||
| Ref 889327 | ClinicalTrials.gov (NCT00097370) Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome | ||||
| Ref 889338 | ClinicalTrials.gov (NCT00274703) An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients | ||||
| Ref 889339 | ClinicalTrials.gov (NCT00358449) Intravenous Mepolizumab In Children With Eosinophilic Esophagitis | ||||
| Ref 889353 | ClinicalTrials.gov (NCT00716651) Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome | ||||
| Ref 889366 | ClinicalTrials.gov (NCT01362244) Mepolizumab in Nasal Polyposis | ||||
| Ref 889367 | ClinicalTrials.gov (NCT01366521) Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils | ||||
| Ref 889370 | ClinicalTrials.gov (NCT01463644) Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis | ||||
| Ref 889372 | ClinicalTrials.gov (NCT01520051) Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations | ||||
| Ref 889380 | ClinicalTrials.gov (NCT01691508) Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma | ||||
| Ref 889381 | ClinicalTrials.gov (NCT01691521) Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma | ||||
| Ref 889382 | ClinicalTrials.gov (NCT01691859) MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects | ||||
| Ref 889385 | ClinicalTrials.gov (NCT01842607) A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects | ||||
| Ref 889393 | ClinicalTrials.gov (NCT02105948) Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients | ||||
| Ref 889394 | ClinicalTrials.gov (NCT02105961) Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD) | ||||
| Ref 889409 | ClinicalTrials.gov (NCT02377427) Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children | ||||
| Ref 889417 | ClinicalTrials.gov (NCT02594332) Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study | ||||
| Ref 889423 | ClinicalTrials.gov (NCT02836496) Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) | ||||
| Ref 889430 | ClinicalTrials.gov (NCT03021304) Study of Mepolizumab Safety Syringe in Asthmatics | ||||
| Ref 889432 | ClinicalTrials.gov (NCT03055195) Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis | ||||
| Ref 889435 | ClinicalTrials.gov (NCT03085797) Effect of Mepolizumab in Severe Bilateral Nasal Polyps | ||||
| Ref 889436 | ClinicalTrials.gov (NCT03099096) Study of Mepolizumab Autoinjector in Asthmatics | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.